Nasdaq · CIK 0001444192
GRCE Grace Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 7 d ago. Close $2.08 on Oct 9, 2026, +2% from the 52-week low and -59% from the high.
Last 90 days
Net insider value
+$449k
more bought than sold
Buys
6
$449k by 2 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
GRCEOct 9, 2026 · close 2.08
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Grace Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Opaleye Management Inc. owner buy | $124k 60,490 shares | +2% | 0% from low-60% from high | |
| 25Weak | Opaleye Management Inc. owner buy | $16k 7,849 shares | +0% | +2% from low-59% from high | |
| 38Weak | Opaleye Management Inc. owner buy | $32k 15,089 shares | +1% | +1% from low-59% from high | |
| 38Weak | Opaleye Management Inc. owner buy | $32k 15,089 shares | +1% | +1% from low-59% from high | |
| 73Notable | Prashant Kohli Chief Executive Officer buy | $214k 100,000 shares | +468% | +3% from low-58% from high | |
| 33Weak | Opaleye Management Inc. owner buy | $32k 15,229 shares | +1% | +2% from low-59% from high |
Transactions
The last 32 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P. | +38,796 | $2.04 | $79k | 2,836,963 | 7 d ago |
| Oct 2, 2026 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P. | +20,000 | $2.07 | $41k | 2,856,963 | 7 d ago |
| Oct 5, 2026 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P. | +1,694 | $2.06 | $3,490 | 2,858,657 | 7 d ago |
| Sep 29, 2026 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P. | +7,849 | $2.09 | $16k | 2,798,167 | 11 d ago |
| Sep 21, 2026 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P. | +9,771 | $2.10 | $21k | 2,785,000 | 11 d ago |
| Sep 23, 2026 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P. | +5,318 | $2.10 | $11k | 2,790,318 | 11 d ago |
| Sep 21, 2026 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P. | +9,771 | $2.10 | $21k | 2,850,000 | 19 d ago |
| Sep 23, 2026 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P. | +5,318 | $2.10 | $11k | 2,855,318 | 19 d ago |
| Sep 17, 2026 | A Brian Davis director | AGrant or award Stock Option (Right to Buy)derivative | - | $0.00 | - | 12,200 | 21 d ago |
| Sep 17, 2026 | George Kottayil director | AGrant or award Stock Option (Right to Buy)derivative | +12,200 | $0.00 | $0 | 12,200 | 21 d ago |
| Sep 17, 2026 | Vimal Kavuru director | AGrant or award Stock Option (Right to Buy)derivative | +12,200 | $0.00 | $0 | 12,200 | 21 d ago |
| Sep 17, 2026 | Edward Neugeboren director | AGrant or award Stock Option (Right to Buy)derivative | +12,200 | $0.00 | $0 | 12,200 | 21 d ago |
| Sep 9, 2026 | Prashant Kohli Chief Executive Officer | POpen-market purchase Common Stock | +100,000 | $2.14 | $214k | 121,357 | 32 d ago |
| Sep 8, 2026 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P. | +9,393 | $2.10 | $20k | 2,769,393 | 32 d ago |
| Sep 9, 2026 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.0001 per shareindirect: By Opaleye, L.P. | +5,836 | $2.09 | $12k | 2,775,229 | 32 d ago |
| Aug 28, 2026 | Prashant Kohli Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +267,160 | $0.00 | $0 | 267,160 | 41 d ago |
| Aug 28, 2026 | R. Loch Macdonald Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +54,690 | $0.00 | $0 | 54,690 | 41 d ago |
| Aug 28, 2026 | Amresh Kumar VP Program Management | AGrant or award Stock Option (Right to Buy)derivative | +35,760 | $0.00 | $0 | 35,760 | 41 d ago |
| Aug 28, 2026 | Robert J DelAversano Principal Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +33,660 | $0.00 | $0 | 33,660 | 41 d ago |
| Jan 8, 2026 | A Brian Davis director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jan 12, 2026 |
| Jan 8, 2026 | Edward Neugeboren director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jan 12, 2026 |
| Jan 8, 2026 | George Kottayil director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jan 12, 2026 |
| Jan 8, 2026 | Vimal Kavuru director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jan 12, 2026 |
| May 9, 2025 | A Brian Davis director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | May 13, 2025 |
| May 9, 2025 | Vimal Kavuru director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | May 13, 2025 |
| May 9, 2025 | Edward Neugeboren director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | May 13, 2025 |
| May 9, 2025 | George Kottayil director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 10,000 | May 13, 2025 |
| Apr 14, 2025 | Carrie D'Andrea VP Clinical Operations | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Apr 16, 2025 |
| Apr 14, 2025 | Robert J DelAversano Principal Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +20,130 | $0.00 | $0 | 20,130 | Apr 16, 2025 |
| Apr 14, 2025 | Prashant Kohli Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +225,400 | $0.00 | $0 | 225,400 | Apr 16, 2025 |
| Apr 14, 2025 | R. Loch Macdonald Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Apr 16, 2025 |
| Apr 14, 2025 | Amresh Kumar VP Program Management | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Apr 16, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Carrie D'AndreaVP Clinical Operations
- A Brian Davisdirector
- Robert J DelAversanoPrincipal Financial Officer
- Vimal Kavurudirector
- Prashant KohliChief Executive Officer
- George Kottayildirector
- Amresh KumarVP Program Management
- R. Loch MacdonaldChief Medical Officer
- Edward Neugeborendirector
- Opaleye Management Inc.owner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.